| Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication. | |
| | |
MedLine Citation:
|
PMID: 8350953 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
One hundred and one patients undergoing anticancer chemotherapy due to hematologic malignancy were retrospectively divided into two groups: 67 patients were treated with ceftriaxone plus amikacin, receiving once daily (od) 2-4 g ceftriaxone, 1-1.5 g amikacin (those without a peripheral or central venous catheter) and 34 patients with central or peripheral venous catheter (CPVC) receiving ceftizidime 2 g three times daily (tid) plus amikacin 0.5 g tid i.v. Both groups were similar as to their isolated pathogens, localization of infection, and basic diagnoses of hematologic malignancies. There was no significant difference in efficacy between ceftriaxone plus amikacin versus ceftazidime plus amikacin, but the toxicity was lower in once daily ceftriaxone plus amikacin group. |
| | |
Authors:
|
V Krcméry; A Danisovicová; L Drgona; S Spánik; P Fuchsberger; S Korec; J Svec |
Related Documents
:
|
23210663 - R-chop with dose-attenuated radiation therapy could induce good prognosis in gastric di... 22993363 - A preliminary study of single intraperitoneal administration of paclitaxel followed by ... 19918303 - Factors affecting results of treatment of hypopharyngeal carcinoma. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Neoplasma Volume: 40 ISSN: 0028-2685 ISO Abbreviation: Neoplasma Publication Date: 1993 |
Date Detail:
|
Created Date: 1993-09-13 Completed Date: 1993-09-13 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0377266 Medline TA: Neoplasma Country: CZECHOSLOVAKIA |
Other Details:
|
Languages: eng Pagination: 103-5 Citation Subset: IM |
Affiliation:
|
Department of Clinical Oncology, Postgraduate Medical School, Bratislava, Slovakia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amikacin
/
adverse effects,
therapeutic use* Antineoplastic Agents / therapeutic use Bacterial Infections / drug therapy*, etiology Candidiasis / drug therapy, etiology Catheterization, Central Venous Catheterization, Peripheral Ceftazidime / adverse effects, therapeutic use* Ceftriaxone / adverse effects, therapeutic use* Drug Therapy, Combination / adverse effects, therapeutic use Hearing / drug effects Humans Kidney / drug effects Leukemia / complications, drug therapy Lymphoma / complications, drug therapy Neutropenia / complications*, etiology Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 37517-28-5/Amikacin; 73384-59-5/Ceftriaxone; 78439-06-2/Ceftazidime |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modulation of leukosialin (sialophorin, CD43 antigen) on the cell surface of human hematopoietic cel...
Next Document: Erythrocyte glutathione peroxidase in patients with colon cancer.